ClinicalTrials.gg
RecruitingNCT07090668Updated Oct 22, 2026

Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease

An interventional study of tAN device in Sickle Cell Disease, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
7 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Anemia, Sickle Cell by Emory University — 4 open to participants now, 6 under way, none of them phase 3. Anemia, Sickle Cell · Emory University.

Planned enrollment
17th of 25
20 · median 24
Started
2025
with 1 other
No phase
12 of 29
3 open now
Registered
28th of 29
by date

Among the 29 studies in Anemia, Sickle Cell by Emory University, this one is the 17th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 with no phase, and was the 28th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 29 studies in Anemia, Sickle Cell by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 7 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Anemia, Sickle Cell by Emory University, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the effects of transauricular vagus and trigeminal nerve stimulation on the treatment of pain in children with Sickle Cell Disease.

  • The primary objective is to determine the feasibility of using a tAN device to treat pain in pediatric participants with SCD by assessing the completion rate, stimulation tolerability, and acceptability of the intervention measures.
  • The secondary objective is to assess the preliminary efficacy of using a tAN device as a remedy for pain in pediatric SCD subjects by analyzing inflammatory serum biomarker levels, the Functional Status Scale (FSS), the Wong-Baker FACES questionnaire, tracking analgesic consumption, and other assessments.
Read the detailed description

The vagus nerve, the body's longest cranial nerve, extends from the brainstem to deep regions of the gastrointestinal tract and plays a vital role in regulating parasympathetic activity across multiple organ systems, including the cardiovascular, respiratory, immune, and nervous systems. Since the early 2000s, vagal nerve stimulation (VNS) has been explored as a therapeutic tool across various diseases, particularly for pain management. VNS can reduce pain by three primary mechanisms: 1) suppressing systemic inflammation, 2) modulating central pain-processing pathways, and 3) alleviating depressive symptoms, which are known to intensify the experience of pain.

Sickle cell disease (SCD) is a genetic blood disorder caused by a point mutation in the β-globin gene, resulting in the production of abnormal hemoglobin (HbS). This leads to polymerization of hemoglobin under low-oxygen conditions, which causes red blood cells to become rigid and sickle-shaped. These malformed cells damage blood vessels and adhere to endothelial surfaces, resulting in vaso-occlusion and impaired blood flow. The subsequent ischemia-reperfusion injury provokes widespread inflammation and produces both acute pain episodes and chronic pain syndromes, often beginning in childhood and persisting throughout life.

The current standard for managing SCD-related pain often involves chronic opioid use, which can lead to dependence, tolerance, and serious side effects. Given the ongoing opioid crisis, there is an urgent need for non-pharmacologic alternatives that are safe, effective, and scalable.

This study proposes the use of transcutaneous auricular vagal nerve stimulation (taVNS) as well as trigeminal auricular nerve stimulation (TAN) -non-invasive methods that stimulates vagal afferents and branches of the trigeminal nerve through the ear-to treat pain in pediatric patients with SCD. taVNS is notable for its excellent safety profile, with minimal to no adverse effects reported in clinical studies. It is a multimodal pain management tool, acting simultaneously on immune, neurologic, and psychological pathways that contribute to pain in SCD.

The innovative aspect of this study lies in its application of a non-invasive, neuroimmune-modulating therapy in a pediatric population with complex pain needs. By potentially reducing the frequency and severity of pain episodes and thereby decreasing reliance on opioids, tAN could transform the clinical approach to pain management in SCD. Ultimately, this research aims to provide a safe, sustainable, and accessible intervention that addresses both the biological and psychosocial dimensions of pain in children and adolescents with SCD.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • sickle cell disease
  • pain management in Sickle cell disease
  • Trans-auricular vagal nerve stimulation
  • trans-auricular nerve stimulation
04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of sickle-cell anemia (HbSS)
  • Normal outer ear anatomy and intact skin for tAN placement
  • Hospitalized for a pain crisis and experiencing pain as a result of SCD
  • Patients must have had at least one prior hospitalization for a sickle cell pain crisis in the past

Exclusion criteria

Exclusion Criteria:

  • History of seizures
  • History of uncontrolled psychiatric illness
  • Repeated episodes of autonomic instability (apnea or bradycardia) that are not self-resolving
  • Cardiomyopathy
  • Diagnosis of Acute Chest Syndrome
  • Unrepaired congenital anomalies affecting the cardiovascular or respiratory system
  • Hemodynamically unstable patients
  • Females who are pregnant or lactating. Subjects who refuse a pregnancy test.
  • Women of , not using adequate as per the investigator's judgment, or not willing to comply with contraception for the duration of the study
  • Patients with a history of surgery within the last 3 months
  • Patients who suffered from a stroke within the last 3 months
  • Patient admitted with a fever or who develops a fever throughout their hospitalization
  • Patients whose disease-modifying therapy (HU, chronic transfusions, etc.) and/or pain medications (gabapentin, pregabalin, etc.) have not yet reached a steady dose
  • Patients who have had 3 or more hospitalizations for acute pain crises in a given year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Controls (Same participant but past data)

    Participants will serve as their own controls. Using chart review, we will collect data from each participant's previous admission for a pain crisis during which they did not receive tAN treatment and compare it to their current admission, during which they are being treated with tAN

  • Experimental
    tAN group

    Subjects admitted to CHOA with SCD pain crisis.

    Device: tAN device

Interventions

  • DevicetAN device

    Sparrow Link tAN device from Spark Biomedical, a non-invasive, adhesive earpiece placed over branches of the trigeminal nerve and vagus nerve near the tragus and mastoid around the ear. The stimulation level is titrated by the investigator to a perceptible but comfortable intensity. Patients cannot adjust the settings themselves, though adjustments can be made upon request. The device consists of a disposable earpiece connected by a cable to a battery-powered controller (3 AAA batteries). It emits a biphasic, rectangular waveform with a 100 µs interphase and a maximum output of 95V.

06

What researchers measure

Primary outcomes

  1. Feasibility: Completion Rate

    Completion rate will be calculated by dividing the number of subjects who successfully used tAN for the duration of the trial, divided by the total number of subjects who participated in the trial. Subjects who prematurely opt to interrupt their participation in the study will not be included in the cohort of patients who successfully completed the study

    Time frame: Through study completion (an average of 3-7 days)

  2. Stimulation tolerability

    Stimulation tolerability will be evaluated daily during hospitalization by asking participants to describe any sensations experienced in response to percutaneous stimulation. Participants will be encouraged to express the sensation in their own words. The investigator will then further clarify the nature of the sensation-such as whether it feels like burning, tingling, or stabbing-to better characterize the participant's experience.

    Time frame: Baseline, everyday throughout the study (an average of 3-7 days)

  3. Acceptability of intervention

    Acceptability of intervention measure will be assessed using a standardized 4 item questionnaire.

    Time frame: Baseline, everyday throughout the study (an average of 3-7 days)

Secondary outcomes

  1. Wong-Baker FACES

    The Wong-Baker FACES Pain Rating Scale is a widely used tool to help individuals-especially children-communicate their level of pain. It uses a series of six cartoon faces, ranging from a happy face at 0 ("No Hurt") to a crying face at 10 ("Hurts Worst"), allowing patients to point to the face that best describes their pain.

    Time frame: Baseline, everyday throughout the study (an average of 3-7 days)

  2. Functional Status Scale(FSS)

    The FSS evaluates six functional domains: Mental Status, Sensory Function, Communication, Motor Function, Feeding, Respiratory Status Each domain is scored on a scale from 1 to 5. Total score range: 6 (best possible function) to 30 (worst possible function)

    Time frame: Baseline, everyday throughout the study (an average of 3-7 days)

  3. Change in Interleukin 6 (IL-6) levels

    IL-6 is a pro-inflammatory cytokine involved in immune responses, inflammation, and infection. Typically \< 5 pg/mL in serum or plasma

    Time frame: Baseline, end of the study (an average of 3-7 days)

  4. Change in MCP-1

    MCP-1 is a pro-inflammatory chemokine that recruits monocytes and other immune cells to sites of inflammation. In children, elevated MCP-1 levels are seen in conditions such as infections, inflammatory diseases Normal levels in healthy children are typically \<100-200 pg/mL

    Time frame: Baseline, end of the study (an average of 3-7 days)

  5. Change in Tumor necrosis factor (TNF-α)

    TNF-α (Tumor Necrosis Factor Alpha) is a key pro-inflammatory cytokine involved in immune activation and systemic inflammation. Normal levels are typically \<10 pg/mL.

    Time frame: Baseline, end of the study (an average of 3-7 days)

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital of Atlanta: Eagelston
    Atlanta, Georgia 30329, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 17 months is below that.

Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jul 2026 → Jan 2027 and completion Jul 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 29, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Jan 2027was Jul 2026
CompletionEst.
Jan 2027was Jul 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Jan 2027
Oct 22, 2026
Study completion
Jul 2026→Jan 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Jul 2026→Jan 2027
    Study completion Jul 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07090668
Lead sponsor
Emory University
Responsible party
Anna Woodbury (Associate Professor, Emory University) — Principal investigator
First posted
Jul 29, 2025
Start date
Aug 12, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Anna Woodbury, MD
Contact
awoodbu@emory.edu
470-882-8960
Vipin Bansal, MD
Contact
vbansa7@emory.edu
404-630-9552
Anna Woodbury, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion